Having trouble accessing articles? Reset your cache.

Roche oral therapy hits endpoint in older SMA patients, offering advantages over Zolgensma, Spinraza

After reporting positive data earlier this year in infants with spinal muscular atrophy, Roche’s risdiplam has now met the primary endpoint in a separate pivotal trial in older patients, paving the way for the therapy to reach a broader patient population than Zolgensma and compete with Spinraza on the basis of dosing convenience.

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE